^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Colorectal Cancer
    Drug:oxaliplatin (DNA synthesis inhibitor, DNA cross linking agent)
    Drug Class:HMG-CoA reductase inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases

    Excerpt:
    ...- Primary tumor (or liver metastasis) of CRC must be KRAS status "mutant"...
    Trial ID:
    BOS3
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Cell Int
    Title:

    Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy

    Published date:
    04/17/2023
    Excerpt:
    We demonstrated that combined administration with statins and L-OHP significantly induced apoptosis and elevated the sensitivity of KRAS-mutated colorectal cancer cells to L-OHP….Therefore, statins may be therapeutically useful as adjuvants to L-OHP in KRAS-mutated colorectal cancer...
    DOI:
    10.1186/s12935-023-02884-z